[Assessment of the genotoxic risk caused by the gyrase inhibitor ofloxacin using sister chromatid exchange rate analysis].
Ofloxacin (Tarivid) is a 4-quinolone of the latest generation. Its mechanism of action is the inhibition of the enzyme gyrase which plays a central role in the bacterial DNA-metabolisms. Thus Ofloxacin blocks the reading of the chromosomes and impairs the cell's function and ability to reduplicate leading to eradication of the pathogens. The genotoxicity of Ofloxacin was assessed by analyses of SCE (sister-chromatid-exchange-rates), which is a sensitive and qualitative parameter indicating chromosomal damages. In vitro no change of the SCE-frequencies could be demonstrated in human lymphocytes; in vivo, however, a slight influence not be excluded, which is also true for eventual additive on synergistic effect with other mutagenic factors.
Kullich
W
W
Ludwig-Boltzmann-Institut für Rehabilitation interner Erkrankungen, Saalfelden.
Brugger
P
P
Klein
G
G
D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin; D010078:Oxazines / Q000009:adverse effects* / Q000627:therapeutic use; D012854:Sister Chromatid Exchange / Q000187:drug effects*; D059005:Topoisomerase II Inhibitors; D014552:Urinary Tract Infections / Q000188:drug therapy*
D010078:Oxazines; D059005:Topoisomerase II Inhibitors; D015242:Ofloxacin
Zur Beurteilung des genotoxischen Risikos durch den Gyrasehemmer Ofloxacin mittels der Bestimmung von Schwesterchromatidaustauschraten.